Similar articles

• Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

  McHutchison J, Sulkowski M. McHutchison J, et al. J Viral Hepat. 2008 Jul;15(7):475-81. doi: 10.1111/j.1365-2893.2008.00973.x. Epub 2008 Mar 24. J Viral Hepat. 2008. PMID: 18363672 Clinical Trial.
• Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.

  Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P; Italian Co-infection Study (ICOS) Group. Cargnel A, et al. Antivir Ther. 2005;10(2):309-17. Antivir Ther. 2005. PMID: 15865225 Clinical Trial.
• [McHutchison's legacy and adherence in hepatitis C].

  Ibarra Barrueta O. Ibarra Barrueta O. Farm Hosp. 2013 Sep-Oct;37(5):424-5. doi: 10.7399/FH.2013.37.5.743. Farm Hosp. 2013. PMID: 24128108 Spanish. No abstract available.
• Pushing the treatment envelope for chronic hepatitis C--is more necessarily better?

  Lutchman G, Ghany M. Lutchman G, et al. Hepatology. 2005 Feb;41(2):234-6. doi: 10.1002/hep.20605. Hepatology. 2005. PMID: 15657958 Review. No abstract available.
• [High dose repeat therapy in previously treated patients with chronic hepatitis C].

  Hoepffner N, Paul KA, Nikodem AB, Teuber G. Hoepffner N, et al. Dtsch Med Wochenschr. 2006 Mar 17;131(11):543-4. doi: 10.1055/s-2006-933693. Dtsch Med Wochenschr. 2006. PMID: 16538557 Review. German. No abstract available.